Oxis Turbuhaler (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate is a bronchodilator that acts on the airway smooth‑muscle pathway to improve airflow.

• Asthma: improves lung function and reduces symptoms when used regularly as maintenance therapy.
• Chronic obstructive pulmonary disease (COPD): provides sustained bronchodilation to ease breathing and decrease exacerbation risk.
• Exercise‑induced bronchoconstriction: helps prevent airway narrowing during physical activity when combined with a rapid‑onset reliever.

• Formoterol binds selectively to β2‑adrenergic receptors on airway smooth‑muscle cells, activating adenylate cyclase and increasing intracellular cyclic AMP. The rise in cAMP leads to relaxation of smooth‑muscle fibers, producing prolonged bronchodilation that lasts up to 12 hours after inhalation.

Formoterol may cause adverse reactions that vary in frequency and severity.

Common Side Effects

• Tremor: mild shaking of the hands or limbs.
• Headache: transient headache episodes.
• Throat irritation: discomfort or dryness in the throat.
• Cough: occasional coughing after inhalation.
• Palpitations: sensation of rapid or irregular heartbeat.

Serious or Rare Side Effects

• Paradoxical bronchospasm: sudden worsening of breathing difficulty.
• Cardiovascular events: chest pain, arrhythmia, or hypertension.
• Hypokalemia: low blood potassium levels.
• Severe allergic reaction: rash, swelling, or anaphylaxis.

When prescribing Formoterol, clinicians should consider several safety aspects.

• Assess asthma or COPD control: ensure patient is stable before initiating therapy.
• Review cardiovascular history: patients with arrhythmias or ischemic heart disease need careful monitoring.
• Avoid excessive dosing: do not exceed the recommended daily inhalations.
• Monitor for paradoxical bronchospasm: discontinue if breathing worsens after use.
• Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Formoterol can interact with other medications that affect the cardiovascular or respiratory systems. Major Interactions (Avoid):\n- Non‑selective β‑blockers: antagonize bronchodilator effect and may precipitate bronchospasm.

• Mono‑mono   

t -   t   -      \